The University of Pittsburgh has climbed to 17th among U.S. universities in patents issued, securing 107 patents and spinning out 15 startup companies in 2025. The milestone reflects a broader strategy to accelerate the journey from scientific discovery to patient treatment, even as research funding faces pressure nationwide.
At a reception held during the BIO International Convention 2026, university leaders outlined how Pittsburgh is positioning itself as a hub for biomanufacturing and rare disease treatments. Anantha Shekhar, senior vice chancellor for the health sciences, noted that the university works directly with UPMC, one of the largest integrated medical centers in the country. “All of this put together presents an incredible opportunity to develop new medicines and test them first in patients right there in Pittsburgh,” Shekhar said.
The university’s approach includes a tiered commercialization support lineup that moves ideas from early hypothesis validation to commercial derisking. This produces partner-ready assets that industry can take forward. Evan Facher, vice chancellor for innovation and entrepreneurship, said the university provides more intellectual property to the community than almost any other U.S. university. “We’re top ranked on all metrics related to the number of patents, the number of deals that we do with pharmaceutical companies,” Facher said. “The ability for Pittsburgh to change the world through health care exists.”
A key advantage, according to leaders, is what no AI company can replicate: deep historical biobanks that offer breadth across conditions and real depth in specific disease areas. That data, combined with the scale of UPMC, allows researchers to study diseases and test therapies in ways that pure computational models cannot match. The event also featured a panel with investors Michael Langer of T.Rx Capital and Debbie Lin of Caris Life Sciences, who discussed the growing value of academic medical center assets in early-stage deals.
Looking ahead, the university is building infrastructure to keep discovery moving regardless of the funding environment. Facher expressed excitement about the collaboration between universities, health care systems, and economic development organizations. “Making Pittsburgh a birthplace for new biotechnology,” he said, is the goal that drives the work every day.